Australian Government

Department of Health

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	234325	K2 Capsules
ARTG entry for	Medicine Listed	
Sponsor	FIT-BioCeuticals Limited	
Postal Address	Care of Blackmores Ltd PO Box 1725, Warriewood, NSW, 2102 Australia	
ARTG Start Date	2/03/2015	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . K2 Capsules

Product Type Single Medicine Product **Effective Date** 7/08/2019

Permitted Indications

Maintain/support teeth mineralisation

Maintain/support bone health

Help maintain/support bone mineralisation

Maintain/support healthy cardiovascular system function

Maintain/support artery health

Maintain/support (state vitamin/mineral/nutrient) levels in the body

Indication Requirements

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Product presentation must not imply or refer to serious cardiovascular conditions.

Product presentation must not imply or refer to circulatory disorders/diseases/conditions e.g. thrombosis.

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1 . Formulation 1

Dosage Form Capsule, soft

Route of Administration	Oral
Visual Identification	

Active Ingredients	
menaquinone 7	**180 microgram**

Other Ingredients (Excipients)
Gelatin
glycerol
iron oxide black
iron oxide red
medium chain triglycerides
purified water
Rice bran oil